Cargando…

Risk of Fungi Associated with Aflatoxin and Fumonisin in Medicinal Herbal Products in the Kenyan Market

Utilization of herbal products is a major concern due to the possibility of contamination by toxigenic fungi that are mycotoxin producers such as Aspergillus species during processing and packaging. Research was carried out to determine the presence of aflatoxins and fumonisins in herbal medicinal p...

Descripción completa

Detalles Bibliográficos
Autores principales: Keter, Lucia, Too, Richard, Mwikwabe, Nicholas, Mutai, Charles, Orwa, Jennifer, Mwamburi, Lizzy, Ndwigah, Stanley, Bii, Christine, Korir, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591901/
https://www.ncbi.nlm.nih.gov/pubmed/28929127
http://dx.doi.org/10.1155/2017/1892972
_version_ 1783262806672408576
author Keter, Lucia
Too, Richard
Mwikwabe, Nicholas
Mutai, Charles
Orwa, Jennifer
Mwamburi, Lizzy
Ndwigah, Stanley
Bii, Christine
Korir, Richard
author_facet Keter, Lucia
Too, Richard
Mwikwabe, Nicholas
Mutai, Charles
Orwa, Jennifer
Mwamburi, Lizzy
Ndwigah, Stanley
Bii, Christine
Korir, Richard
author_sort Keter, Lucia
collection PubMed
description Utilization of herbal products is a major concern due to the possibility of contamination by toxigenic fungi that are mycotoxin producers such as Aspergillus species during processing and packaging. Research was carried out to determine the presence of aflatoxins and fumonisins in herbal medicinal products sold in Eldoret and Mombasa towns in Kenya. The study employed both exploratory and laboratory experimental design. The herbal products were purchased from the market and transported to Kenya Medical Research Institute for processing and analysis. Fungal contaminants were determined according to Pharmacopoeia specifications. The toxins were quantified using ELISA based technique. The genus Aspergillus was the most dominant followed by Penicillium. Fungal counts ranged between 1 CFU/g and >1000 cfu/g. Analysis of variance showed that the rate of fungal contaminants for Eldoret and Mombasa samples had significant association (p ≤ 0.001). Aflatoxin levels ranged from 1 to 24 ppb, while fumonisin levels ranged from 1 to >20 ppb. Only 31% of samples met the standards for microbial limits as specified in Pharmacopoeia. There is need for product microbial quality improvement through proper harvesting, processing, storage, and marketing. It is recommended that a policy be enacted to enable regulation of herbal products in Kenya.
format Online
Article
Text
id pubmed-5591901
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-55919012017-09-19 Risk of Fungi Associated with Aflatoxin and Fumonisin in Medicinal Herbal Products in the Kenyan Market Keter, Lucia Too, Richard Mwikwabe, Nicholas Mutai, Charles Orwa, Jennifer Mwamburi, Lizzy Ndwigah, Stanley Bii, Christine Korir, Richard ScientificWorldJournal Research Article Utilization of herbal products is a major concern due to the possibility of contamination by toxigenic fungi that are mycotoxin producers such as Aspergillus species during processing and packaging. Research was carried out to determine the presence of aflatoxins and fumonisins in herbal medicinal products sold in Eldoret and Mombasa towns in Kenya. The study employed both exploratory and laboratory experimental design. The herbal products were purchased from the market and transported to Kenya Medical Research Institute for processing and analysis. Fungal contaminants were determined according to Pharmacopoeia specifications. The toxins were quantified using ELISA based technique. The genus Aspergillus was the most dominant followed by Penicillium. Fungal counts ranged between 1 CFU/g and >1000 cfu/g. Analysis of variance showed that the rate of fungal contaminants for Eldoret and Mombasa samples had significant association (p ≤ 0.001). Aflatoxin levels ranged from 1 to 24 ppb, while fumonisin levels ranged from 1 to >20 ppb. Only 31% of samples met the standards for microbial limits as specified in Pharmacopoeia. There is need for product microbial quality improvement through proper harvesting, processing, storage, and marketing. It is recommended that a policy be enacted to enable regulation of herbal products in Kenya. Hindawi 2017 2017-08-08 /pmc/articles/PMC5591901/ /pubmed/28929127 http://dx.doi.org/10.1155/2017/1892972 Text en Copyright © 2017 Lucia Keter et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Keter, Lucia
Too, Richard
Mwikwabe, Nicholas
Mutai, Charles
Orwa, Jennifer
Mwamburi, Lizzy
Ndwigah, Stanley
Bii, Christine
Korir, Richard
Risk of Fungi Associated with Aflatoxin and Fumonisin in Medicinal Herbal Products in the Kenyan Market
title Risk of Fungi Associated with Aflatoxin and Fumonisin in Medicinal Herbal Products in the Kenyan Market
title_full Risk of Fungi Associated with Aflatoxin and Fumonisin in Medicinal Herbal Products in the Kenyan Market
title_fullStr Risk of Fungi Associated with Aflatoxin and Fumonisin in Medicinal Herbal Products in the Kenyan Market
title_full_unstemmed Risk of Fungi Associated with Aflatoxin and Fumonisin in Medicinal Herbal Products in the Kenyan Market
title_short Risk of Fungi Associated with Aflatoxin and Fumonisin in Medicinal Herbal Products in the Kenyan Market
title_sort risk of fungi associated with aflatoxin and fumonisin in medicinal herbal products in the kenyan market
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591901/
https://www.ncbi.nlm.nih.gov/pubmed/28929127
http://dx.doi.org/10.1155/2017/1892972
work_keys_str_mv AT keterlucia riskoffungiassociatedwithaflatoxinandfumonisininmedicinalherbalproductsinthekenyanmarket
AT toorichard riskoffungiassociatedwithaflatoxinandfumonisininmedicinalherbalproductsinthekenyanmarket
AT mwikwabenicholas riskoffungiassociatedwithaflatoxinandfumonisininmedicinalherbalproductsinthekenyanmarket
AT mutaicharles riskoffungiassociatedwithaflatoxinandfumonisininmedicinalherbalproductsinthekenyanmarket
AT orwajennifer riskoffungiassociatedwithaflatoxinandfumonisininmedicinalherbalproductsinthekenyanmarket
AT mwamburilizzy riskoffungiassociatedwithaflatoxinandfumonisininmedicinalherbalproductsinthekenyanmarket
AT ndwigahstanley riskoffungiassociatedwithaflatoxinandfumonisininmedicinalherbalproductsinthekenyanmarket
AT biichristine riskoffungiassociatedwithaflatoxinandfumonisininmedicinalherbalproductsinthekenyanmarket
AT korirrichard riskoffungiassociatedwithaflatoxinandfumonisininmedicinalherbalproductsinthekenyanmarket